U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414836) titled 'A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors' on Feb. 11.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: BG-C0979
Administered by intravenous infusion.
DRUG: Tislelizumab
Administered by ...